New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2024, Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection.
View latest version (2024)Bibliographic information
GuidelineGuidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
Year of Publication2015
Issuing InstitutionWorld Health Organization
Recommendation
Retired
FIRST-LINE ANTIVIRAL THERAPIES FOR CHRONIC HEPATITIS B. In all adults, adolescents and children aged 12 years or older in whom antiviral therapy is indicated, the nucleos(t)ide analogues (NAs) which have a high barrier to drug resistance (tenofovir or entecavir) are recommended. Entecavir is recommended in children aged 2–11 years
Recommended in favor
Strong
Certainty of evidence
Moderate